<DOC>
	<DOCNO>NCT00448890</DOCNO>
	<brief_summary>GSK729327 selective positive allosteric modulator AMPA-type ionotropic glutamate receptor , exhibit equivalent potency AMPA receptor subtypes . On basis preclinical study expect compound improve cognitive measure schizophrenic patient acceptable safety . This First Time Human Study ( FTIH ) ass safety , tolerability , pharmacokinetics preliminary pharmacodynamics GSK729327 healthy volunteer . The study conduct 2 part , single dos explore Part A multiple dose 28 day Part B . Part A single blind , placebo control , single oral dose , dose-rising cross-over study healthy male volunteer . Subjects randomize two cohort alternate panel design . There nine dosing session total order investigate 7 different dos . The initial dose 0.25 mg subsequent dos determine base pharmacokinetic safety result previous dose . Part B randomise , single blind , placebo-controlled , parallel group study repeat oral dose GSK729327 . Up 4 cohort 15 ( 12 subject receive active dose 3 subject receive placebo ) healthy male female ( non-childbearing potential ) volunteer enrol Part B .</brief_summary>
	<brief_title>Evaluation Single Repeat Doses GSK729327 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy male subject age 18 55 year inclusive . Part B also include healthy female subject nonchild bear potential . A normal ECG , physical examination laboratory screen . Body weight &gt; 50 kg BMI within range 18.529.9 kg/m2 inclusive . Signed date write informed consent prior admission study . Abuse alcohol . A positive prestudy urine drug alcohol screen . A positive prestudy HIV , Hepatitis B surface antigen positive Hepatitis C antibody result screen . History DSMIV alcohol and/or drug abuse dependence . Consumption grapefruit juice grapefruit within 7 day prior first dose study medication final evaluation . Has receive investigational drug participate research trial within 30 day 5 halflives , twice duration biological effect drug ( ever longer ) prior first dose study medication . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug within 4 week prior first dose study medication final evaluation . Where participation study would result donation blood excess 500 ml within 56 day period . History presence allergy study drug drug class , history drug allergy , opinion physician responsible , contraindicate participation . History presence clinically significant gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . History cholecystectomy biliary tract disease . History regular use tobacco nicotinecontaining product within 6 month start study . An unwillingness male subject use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication 90 day follow administration last dose study medication.QTc interval &gt; 450 ms. Or ECG suitable QT measurement . History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . The subject history myocardial infarction .The subject rest pulse rate &lt; 55 &gt; 100 bpm OR systolic blood pressure &gt; 140 &lt; 100 OR diastolic blood pressure &gt; 90 &lt; 60.Current past history symptomatic orthostatic hypotension . The subject laboratory abnormality investigator 's judgment consider clinically significant ( even outside specify range ) .History know suspected seizure , include infantile febrile , unexplained significant recent loss consciousness history significant head trauma loss consciousness family history ( first degree relative ) epilepsy seizure ( fit ) .History presence psychiatric disease . History suicidal attempt behavior . Subjects complete neuropsychological test battery despite undergone training session . Subject history sleep problem last 3 month . The subject clinically significant abnormality haematology , blood chemistry , ECG , physical examination resolve screening visit . Abnormal response photic stimulation EEG . Abnormal prolactin TSH free T4 free T3 screening/baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>AMPA positive modulator , healthy volunteer</keyword>
</DOC>